Fortress Biotech, Inc. Share Price Nasdaq

FBIOP

US34960Q2084

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 06/10/2026 BST			5-day change	1st Jan Change
18.58 ^USD	+2.65%		+11.46%	+95.79%

08-13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Valuation: Fortress Biotech, Inc.

Market Cap	68.37M 60.69M 56.8M 51.48M 97.22M 6.59B 97.93M 682M 265M 3.36B 257M 251M 10.81B	P/E 2026 *	0.8x	P/E 2027 *	-2.05x
Enterprise Value	68.37M 60.69M 56.8M 51.48M 97.22M 6.59B 97.93M 682M 265M 3.36B 257M 251M 10.81B	EV / Sales 2026 *	0.87x	EV / Sales 2027 *	0.6x
Free-Float	77.3%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news: Fortress Biotech, Inc.

08-13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026
05-14	Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Journey Medical Corporation secures contract with third major GPO for Emrosi	RE
03-31	Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Fortress Biotech Unit Closes $205 Million PRV Sale	MT
02-23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
01-13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE
01-13	Fortress Biotech seen surging after FDA approval
01-13	Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo	CI
01-13	Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell	MT
01-13	US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease	RE
01-13	Fortress Biotech and Cyprium Therapeutics announce U.S. FDA approval of Zycubo® (copper histidinate), the first and only approved treatment for Menkes disease in the United States	RE

More news

Last Transcript: Fortress Biotech, Inc.

Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026

08-13

More transcripts

Analysts' recommendations: Fortress Biotech, Inc.

01/10/25	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101	CI
01/10/25	Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility	DJ
01/10/25	Fortress Biotech and Cyprium Therapeutics announce an update on the NDA for CUTX-101	RE
19/03/24	Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	MT
29/11/23	Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	MT

More recommendations

Press Releases: Fortress Biotech, Inc.

09-08	Journey Medical Corporation to Participate in September 2026 Investor Conferences	AQ
09-08	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-13	Fortress Biotech: Q2 Earnings Snapshot	AQ
08-13	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
08-12	Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ

More press releases

News in other languages: Fortress Biotech, Inc.

01-13	Fortress Biotech attendu en forte hausse après une approbation de la FDA
29/09/21	MÄRKTE USA/Nur maue Erholung - Belastungsfaktoren bleiben
29/09/21	MÄRKTE USA/Moderate Erholung von Vortagesabsturz
30/09/20	Israël limite les manifestations dans le cadre de mesures sanitaires
30/09/20	France : l'inflation a ralenti à 0,1% sur un an en septembre

More news

Managers and Directors: Fortress Biotech, Inc.

Manager	Title	Age	Since
Lindsay Rosenwald CEO	Chief Executive Officer	71	19/12/2013
Xiao Qin Lu DFI	Director of Finance/CFO	51	21/02/2012
David Jin DFI	Director of Finance/CFO	36	15/08/2022

Director	Title	Age	Since
Jimmie Harvey BRD	Director/Board Member	74	30/11/2008
Lindsay Rosenwald CHM	Chairman	71	19/12/2013
J. Jay Lobell BRD	Director/Board Member	63	31/05/2006

More insiders

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13RÎ±2 CAR T Cell Program for Glioblastoma), and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/10/26	US$18.58	+2.65%	4,885
05/10/26	US$18.10	+7.35%	30,165
02/10/26	US$16.86	+4.98%	25,188
01/10/26	US$16.06	-2.73%	7,287
30/09/26	US$16.51	-0.96%	16,218

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.050USD

Average target price

5.000USD

Spread / Average Target

+143.90%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Fortress Biotech, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fortress Biotech, Inc.

Company calendar

As early as today, start finding the best investment opportunities!

Markets		Quality
Nasdaq	FBIOP	Delayed
CBOE	FBIOP	Real-time
Deutsche Boerse AG	CNB0	Delayed

1 day	+2.65%
1 week	+11.46%
Current month	+12.54%
1 month	-0.91%
3 months	-8.16%
6 months	+36.42%
Current year	+95.79%

1 week	16.05	18.58
1 month	16.04	18.76
Current year	9.49	21.43
1 year	6.27	21.43
3 years	4.72	21.43
5 years	4.72	26.6
10 years	0	26.69

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORTRESS BIOTECH, INC.	+2.65%	+11.46%	-	-	69.7M
ELI LILLY AND COMPANY	+1.26%	-2.29%	+36.97%	+104.79%	1,019B
JOHNSON & JOHNSON	+0.73%	-4.78%	+35.41%	+61.62%	610B
ABBVIE INC.	+0.35%	+1.29%	+15.86%	+79.90%	470B
MERCK & CO., INC.	+1.72%	-4.92%	+59.84%	+36.64%	344B
ROCHE HOLDING AG	+0.26%	+0.14%	+21.29%	+40.99%	336B
NOVARTIS AG	+0.60%	-3.09%	+10.76%	+32.59%	266B
ASTRAZENECA PLC	+1.65%	-3.78%	-6.03%	+9.29%	241B
AMGEN INC.	-0.09%	-4.97%	+36.88%	+50.52%	218B
GILEAD SCIENCES, INC.	-0.28%	-4.66%	+26.99%	+92.98%	179B
Average	+0.60%	-3.71%	+26.44%	+56.59%	409.2B
Weighted average by Cap.	+0.05%	-3.43%	+29.52%	+67.02%

	2026 *	2027 *
Net sales	78.79M 69.95M 65.46M 59.33M 112M 7.6B 113M 786M 306M 3.87B 296M 289M 12.46B	113M 101M 94.08M 85.27M 161M 10.92B 162M 1.13B 439M 5.57B 425M 416M 17.9B
Net income	88.25M 78.34M 73.31M 66.45M 125M 8.51B 126M 880M 342M 4.34B 331M 324M 13.95B	-37.81M -33.57M -31.41M -28.47M -53.77M -3.65B -54.16M -377M -147M -1.86B -142M -139M -5.98B
Net Debt	-	-

Fortress Biotech, Inc. Share Price Nasdaq

Stocks

FBIOP

US34960Q2084

Pharmaceuticals

Valuation: Fortress Biotech, Inc.

Chart: Fortress Biotech, Inc.

Latest news: Fortress Biotech, Inc.

Last Transcript: Fortress Biotech, Inc.

Analysts' recommendations: Fortress Biotech, Inc.

Press Releases: Fortress Biotech, Inc.

News in other languages: Fortress Biotech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Fortress Biotech, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise